Modeling the Modern Cannabinoid Formulations

By |2026-11-04T10:42:36-08:0010/05/2026|Cannabinoids|

Developing cannabinoids into clinical-grade drug candidates requires navigating significant physicochemical hurdles, including low oral bioavailability, highly variable first-pass metabolism, and chemical instability. In our latest guest article on the R3CR blog, Milind Upadhyay, Chief Executive Officer of Formulaite Inc., examines how mechanistic simulation tools like physiologically based pharmacokinetic (PBPK) modeling and density functional theory (DFT) enable research teams to evaluate formulation behavior and patient variability in silico. He also details how these computational approaches align with current regulatory expectations, including the finalized ICH M15 guidance.